Insulin resistance: The cardiovascular aspect

Hormone and Metabolic Research

Volumn 40, Issue 9, 2008, Pages 583-587

  Dominguez, H ^a   Flyvbjerg, A ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INSULIN; NATEGLINIDE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TELMISARTAN;

ATHEROSCLEROSIS; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; EDITORIAL; HEART ATRIUM FIBRILLATION; HEART MUSCLE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN BINDING; INSULIN RELEASE; INSULIN RESISTANCE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RECEPTOR BINDING; VASCULAR RESISTANCE;

CARDIOVASCULAR SYSTEM; HUMANS; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; POSTPRANDIAL PERIOD; VENTRICULAR REMODELING;

EID: 53649110136     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1082084     Document Type: Editorial

References (91)

1. Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care 1985; 8: 230-234
2. Cooper RS, Pacold IV, Ford ES. Age-related differences in case-fatality rates among diabetic patients with myocardial infarction. Findings from National Hospital Discharge Survey, 1979-1987. Diabetes Care 1991; 14: 903-908
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234
4. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-2581
5. Javaid A, Steinberg DH, Buch AN, Corso PJ, Boyce SW, Pinto Slottow TL, Roy PK, Hill P, Okabe T, Torguson R, Smith KA, Xue Z, Gevorkian N, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R. Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery disease. Circulation 2007; 116: 1200-1206
6. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA 2005; 293: 1501-1508
7. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008; 117: 261-295
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
9. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. Diabetes 1982; 31 (Suppl 5): 1-81
10. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393
11. Goede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591
12. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Gog DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99:21i-33i
13. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-1214
14. Rewers M, Zaccaro D, D'Agostino R, Haffner S, Saad MF, Selby JV, Bergman R, Savage P. Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004; 27: 781-787
15. Tenenbaum A, Adler Y, Boyko V, Tenenbaum H, Fisman EZ, Tanne D, Lapidot M, Schwammenthal E, Feinberg MS, Matas Z, Motro M, Behar S. Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery disease. Am Heart J 2007; 153: 559-565
16. Bigazzi R, Bianchi S, Buoncristiani E, Campese VM. Increased cardiovascular events in hypertensive patients with insulin resistance: A 13-year follow-up. Nutr Metab Cardiovasc Dis 2008; 18: 314-319
17. Jeppesen J. Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol 2007; 49: 2112-2119
18. Tenerz A, Lonnberg I, Berne C, Nilsson G, Leppert J. Myocardial infarction and prevalence of diabetes mellitus. Is increased casual blood glucose at admission a reliable criterion for the diagnosis of diabetes? Eur Heart J 2001; 22: 1102-1110
19. Wilkin TJ. Changing perspectives in diabetes: their impact on its classification. Diabetologia 2007; 50: 1587-1592
20. Marzio D Di, Mohn A, Martino M de, Chiarelli F. Macroangiopathy in adults and children with diabetes: risk factors (part 2). Horm Metab Res 2006; 38: 706-720
21. Marzio D Di, Mohn A, Mokini ZH, Giannini C, Chiarelli F. Macroangiopathy in adults and children with diabetes: from molecular mechanisms to vascular damage (part 1). Horm Metab Res 2006; 38: 691-705
22. Ferrannini E, Balkau B, Coppack SW, Dekker JM, Mari A, Nolan J, Walker M, Natali A, Beck-Nielsen H. Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin Endocrinol Metab 2007; 92: 2885-2892
23. Maahs DM, Snively BM, Bell RA, Dolan L, Hirsch I, Imperatore G, Linder B, Marcovina SM, Mayer-Davis EJ, Pettitt DJ, Rodriguez BL, Dabelea D. Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for Diabetes in Youth study. Diabetes Care 2007; 30: 2593-2598
24. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care 2007; 30: 707-712
25. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP. Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 2007; 30: 2314-2320
26. Simonson GD, Kendall DM. Diagnosis of insulin resistance and associated syndromes: the spectrum from the metabolic syndrome to type 2 diabetes mellitus. Coron Artery Dis 2005; 16: 465-472
27. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85-96
28. Arnqvist HJ. The role of IGF-system in vascular insulin resistance. Horm Metab Res 2008; 40: 588-592
29. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376
30. Shaul PW. Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J Physiol 2003; 547: 21-33
31. Taddei S, Virdis A, Mattei P, Natali A, Ferrannini E, Salvetti A. Effect of insulin on acetylcholine-induced vasodilation in normotensive subjects and patients with essential hypertension. Circulation 1995; 92: 2911-2918
32. Utriainen T, Malmstrom R, Makimattila S, Yki-Jarvinen H. Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia 1995; 38: 555-564
33. Stepp DW. Impact of obesity and insulin resistance on vasomotor tone: nitric oxide and beyond. Clin Exp Pharmacol Physiol 2006; 33: 407-414
34. Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007; 3: 46-56
35. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610
36. Hermann TS, Rask-Madsen C, Ihlemann N, Dominguez H, Jensen CB, Storgaard H, Vaag AA, Kober L, Torp-Pedersen C. Normal insulin-stimulated endothelial function and impaired insulin-stimulated muscle glucose uptake in young adults with low birth weight. J Clin Endocrinol Metab 2003; 88: 1252-1257
37. Schulman IH, Zhou MS, Jaimes EA, Raij L. Dissociation between metabolic and vascular insulin resistance in aging. Am J Physiol Heart Circ Physiol 2007; 293: H853-H859
38. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575
39. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven CM, Cooke JP. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydroiase. Circulation 2002; 106: 987-992
40. Sydow K, Hornig B, Arakawa N, Bode-Boger SM, Tsikas D, Munzel T, Boger RH. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA. Vasc Med 2004; 9: 93-101
41. Harja E. Bu DX. Hudson BI. Chang JS, Shen X, Hallam K, Katea AZ, Lu Y, Rosario RH, Oruganti S, Nikolla Z, Belov D, Lalla E, Ramasamy R, Yan SF, Schmidt AM. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE mice. J Clin Invest 2008; 118: 183-194
42. Achan V, Broadhead M, Mataki M, Whitley G, Leiper J, MacAllister R, Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydroiase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-1459
43. Toutouzas K, Riga M, Stefanadi E, Stefanadis C. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance. Horm Metab Res 2008; 40: 655-659
44. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1-R12
45. Okon EB, Colbabaie A, Breemen C van. Paracrine effects of endothelial cells in a diabetic mouse model: capacitative calcium entry stimulated thromboxane release. Horm Metab Res 2008; 40: 645-650
46. Figueroa XF, Chen CC, Campbell KP, Damon DN, Day KH, Ramos S, Duling BR. Are voltage-dependent ion channels involved in the endothelial cell control of vasomotor tone? Am J Physiol Heart Circ Physiol 2007; 293: H1371-H1383
47. Yashiro Y, Duling BR. Integrated Ca(2+) signaling between smooth muscle and endothelium of resistance vessels. Circ Res 2000; 87: 1048-1054
48. Bolon ML, Kidder GM, Simon AM, Tyml K. Lipopolysaccharide reduces electrical coupling in microvascular endothelial cells by targeting connexin40 in a tyrosine-, ERK1/2-, PKA-, and PKC-dependent manner. J Cell Physiol 2007; 211: 159-166
49. Rai A, Riemann M, Gustafsson F, Holstein-Rathlou NH, Torp-Pedersen C. Streptozotocin-induced diabetes decreases conducted vasoconstrictor response in mouse cremaster arterioles. Horm Metab Res 2008; 40: 651-654
50. Brodsky SV, Gao S, Li H, Goligorsky MS. Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells. Am J Physiol Heart Circ Physiol 2002; 283: H2130-H2139
51. Cosentino F, Eto M, Paolis P De, Loo B van der. Bachschmid M, Ullrich V, Kouroedov A, Delli Gatti C, Joch H, Volpe M, Luscher TF. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 2003; 107: 1017-1023
52. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790
53. Bellin C, Wiza DH de, Wiernsperger NF, Rosen P. Generation of reactive oxygen species by endothelial and smooth muscle cells: influence of hyperglycemia and metformin. Horm Metab Res 2006; 38: 732-739
54. Kass DA. Getting better without AGE: new insights into the diabetic heart. Circ Res 2003; 92: 704-706
55. Kass DA, Shapiro EP. Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001: 104: 1464-1470
56. Schalkwijk CG, Brouwers O, Stehouwer CDA. Modulation of insulin action by advanced glycation endproducts: a new player in the field. Horm Metab Res 2008; 40: 614-619
57. Nishizawa Y, Koyama H. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease. J Ren Nutr 2008; 18: 76-82
58. Yoshida T, Yamagishi S, Nakamura K, Matsui T. Imaizumi T, Takeuchi M, Koga H, Ueno T, Sata M. Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation. Horm Metab Res 2008; 40: 620-625
59. Colette C, Monnier L. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes. Horm Metab Res 2007; 39: 683-686
60. Monnier L, Mas E, Ginet C, Michel F, Villon L. Cristol JP. Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hypergiycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681-1687
61. Hanefeld M, Ceriello A, Schwarz PE, Bornstein SR. The metabolic syndrome - a postprandial disease? Horm Metab Res 2006; 38: 435-436
62. Ceriello A, Davidson J, Hanefeld M, Letter L, Monnier L, Owens D. Tajima N, Tuomilehto J. Postprandial hypergiycaemia and cardiovascular complications of diabetes: an update. Nutr Metab Cardiovasc Dis 2006; 16: 453-456
63. Bloomgarden ZT. Insulin resistance, dyslipidemia, and cardiovascular disease. Diabetes Care 2007; 30: 2164-2170
64. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240
65. Qiao Q. Tuomilehto J, Borch-Johnsen K. Post-challenge hypergiycaemia is associated with premature death and macrovascular complications. Diabetologia 2003; 46 (Suppl 1): M17-M21
66. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an alphaglucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 1998; 21: 1720-1725
67. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161
68. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-16
69. Major-Pedersen A, Ihlemann N, Hermann TS, Christiansen B, Kveiborg B, Dominguez H, Nielsen D, Rask-Madsen C, Svendsen OL, Køber L. Torp-Pedersen C. Effects of acute and chronic attenuation of postprandial hyperglycemia on postglucose-load endothelial function in insulin resistant individuals: Is stimulation of first phase insulin secretion beneficial for the endothelial function? Horm Metab Res 2008; 40: 607-613
70. Schmitz G, Langmann T. Metabolic learning in the intestine: adaptation to nutrition and luminal factors. Horm Metab Res 2006; 38: 452-454
71. Creutzfeldt W. Entero-insular axis and diabetes mellitus. Horm Metab Res 1992; 26 (Suppl): 13-18
72. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A. Juul AG. Hoist JJ. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 2706-2713
73. Muscelli E, Mari A, Casolaro A, Camastra S, Seghieri G, Gastaldelli A. Hoist JJ, Ferrannini E. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57(5): 1340-1348
74. Knop FK, Vilsboll T, Hojberg PV, Larsen S, Madsbad S. Volund A, Hoist JJ, Krarup T. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007; 56: 1951-1959
75. Nyström T. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res 2008; 40: 593-606
76. Liang CP, Han S, Senokuchi T, Tall AR. The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ Res 2007; 100: 1546-1555
77. Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arteriosder Thromb Vasc Bioi 2007; 27: 2276-2283
78. Konukoglu D, Hatemi H, Bayer H, Bagriacik N. Relationship between serum concentrations of interleukin-6 and tumor necrosis factor alpha in female Turkish subjects with normal and impaired glucose tolerance. Horm Metab Res 2006; 38: 34-37
79. Yudkin JS. Inflammation, obesity, and the metabolic syndrome. Horm Metab Res 2007; 39: 707-709
80. Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, Ihlemann N, Baunbjerg Nielsen D, Spohr C, Kober L, Vaag A, Torp-Pedersen C. Metabolic and vascular effects of tumor necrosis factoralpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005; 42: 517-525
81. Larsen CM, Faulenbach M, Vaag A, Volund A, Eases JA, Seifert B, Mandrup-Poulsen T, Donath MY. lnterleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526
82. Andersen A, Pedersen BK. The role of inflammation in vascular insulin resistance with focus on IL-6. Horm Metab Res 2008; 40: 635-639
83. Bjerre M, Hansen TK, Flyvbjerg A. Complement activation and cardiovascular disease. Horm Metab Res 2008; 40: 626-634
84. Paolisso C, Galderisi M, Tagliamonte MR, Divitis M de, Galzerano D, Petrocelli A, Gualdiero P, Divitis O de, Varricchio M. Myocardial wall thickness and left ventricular geometry in hypertensives. Relationship with insulin. Am J Hypertens 1997; 10: 1250-1256
85. Giles TD. The patient with diabetes mellitus and heart failure: at-risk issues. Am J Med 2003; 115 (Suppl 8A): 107S-110S
86. Sundstrom J, Lind I, Nystrom N, Zethelius B, Andren B, Hales CN, Lithell HO. Left ventricular concentric remodeling rather than left ventricular hypertrophy is related to the insulin resistance syndrome in elderly men. Circulation 2000; 101: 2595-2600
87. Wong C, Marwick TH. Obesity cardiomyopathy: diagnosis and therapeutic implications. Nat Clin Pract Cardiovasc Med 2007; 4: 480-490
88. Wong C, Marwick TH. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med 2007; 4: 436-443
89. Ha JW, Lee HC, Kang ES, Ahn CM, Kim JM, Ahn JA, lee SW, Choi EY, Rim SJ, Oh JK, Chung N. Abnormal left ventricular longitudinal functional reserve in patients with diabetes mellitus: implication for detecting subclinical myocardial dysfunction using exercise tissue Doppler echocardiography. Heart 2007; 93: 1571-1576
90. Kato T, Yamashita T, Sekiguchi A, Sagara K, Takamura M, Takata S, Kaneko S, Aizawa T, Fu LT. What are arrhythmogenic substrates in diabetic rat atria? J Cardiovasc Electrophysiol 2006; 17: 890-894
91. Yamagishi S, Matsui T, Nakamura K. Possible molecular mechanisms by which angiotensin II type 1 receptor blockers (ARBs) prevent the development of atrial fibrillation in insulin resistant patients. Horm Metab Res 2008; 40: 640-644